FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

In our exclusive interview, Dr. Drilon provided background on use of targeted therapy in advanced NSCLC, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.